IceCure Medical Regains Nasdaq Listing Compliance

The Nasdaq staff confirmed the resolution of the bid price deficiency in a written notice issued on June 18, 2026. This decision followed a consistent performance period between June 4 and June 17, during which the company's ordinary shares met the $1.00 minimum bid price requirement set forth in Listing Rule 5550(a)(2). With this milestone achieved, the exchange now considers the matter closed.

IceCure specializes in liquid-nitrogen-based systems designed to destroy both benign and malignant tumors by freezing. The company’s flagship ProSense platform offers a minimally invasive alternative to traditional surgical removal for patients dealing with breast, kidney, lung, and bone cancers. The technology is currently cleared for clinical use across several global markets, including the United States, Europe, and Asia.